Theranostical nanosystem‐mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma

Yu Guo, Jing Wang, Lu Zhang, Shunli Shen, Ruomi Guo, Yang Yang, Wenjie Chen, Yiru Wang, Guihua Chen, Xintao Shuai – 17 December 2015 – Because the primary surgical treatment options for hepatocellular carcinoma (HCC)—including hepatic resection and liver transplantation—often fail due to recurrence and metastasis, identifying early prognostic biomarkers and therapeutic targets for HCC is of great importance.

Hippocalcin‐like 1 suppresses hepatocellular carcinoma progression by promoting p21Waf/Cip1 stabilization by activating the ERK1/2‐MAPK pathway

Yonglong Zhang, Yanfeng Liu, Jinlin Duan, Haibo Yan, Jun Zhang, Huilu Zhang, Qi Fan, Feifei Luo, Guoquan Yan, Ke Qiao, Jie Liu – 13 December 2015 – Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related death. However, the underlying mechanism during hepatocarcinogenesis remains unclarified. Stable isotope labeling by amino acids in cell culture (SILAC) is a powerful quantitative strategy for proteome‐wide discovery of novel biomarkers in cancers. Hippocalcin‐like 1 (HPCAL1) is a calcium sensor protein.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

Marta Cavallin, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Anna Chiara Frigo, Gianpiero Benetti, Elisabetta Gola, Filippo Morando, Marialuisa Stanco, Silvia Rosi, Antonietta Sticca, Umberto Cillo, Paolo Angeli – 13 December 2015 – In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared.

Subscribe to